One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
AlloVir logo
AlloVir ALVR
report update icon

Quarterly report 2026-Q3
added 11-10-2026

AlloVir Cash Flow 2025-2011 | ALVR

Brief overview of AlloVir's cash generation

Cash flow changes are traced through the five latest available reports from 2021 to 2025.

At the end of the period, operations consumed -$38.4 million rather than generating cash. This profile calls for caution.

Only 0 of five observations were above zero. The business relies heavily on individual strong periods.

Overall picture

AlloVir has limited cash flow resilience; a return to stable positive cash generation is the main condition for improvement.

Annual Cash Flow AlloVir

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-38.4 M -20.7 M -124 M -142 M -106 M -60.8 M -20.2 M - - - - - - - -

Depreciation & Amortization

13 K - 398 K 723 K 189 K 73 K 19 K - - - - - - - -

Accounts Payables

1.28 M 1.56 M 6.76 M 3 M 8.36 M 963 K - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow AlloVir

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- -11 M -11.6 M -7.06 M -11.3 M -12.5 M -7.44 M - - -3.97 M -4.52 M -30.7 M -34.5 M -27.1 M -32.1 M -31.6 M -35.1 M -28.9 M -46.5 M -28.1 M -36.4 M -22.9 M -18.9 M -21.1 M -18.1 M -21.7 M -10.5 M - -11.3 M -4.88 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

- 10 K 10 K 10 K - - - - - - - 143 K 86 K 85 K 86 K 63 K 85 K 86 K 466 K 105 K 44 K 33 K 18 K - 18 K 37 K 18 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

2.75 M 1.12 M 905 K 1.28 M 494 K 3.68 M 2.37 M 1.56 M 51 K 110 K 765 K 6.76 M 3.92 M 5.16 M 4.13 M 3 M 4.89 M 5.52 M 4.47 M 8.36 M 133 K 4.2 M 2.06 M 963 K 1.84 M 680 K 963 K 630 K 630 K 630 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company AlloVir, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Windtree Therapeutics Windtree Therapeutics
WINT
- - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 4.2 -0.36 % $ 651 M usaUSA
AbbVie AbbVie
ABBV
$ 294.72 0.32 % $ 521 B usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.78 0.89 % $ 296 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 316.97 4.77 % $ 24.7 B usaUSA
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
- -60.05 % $ 125 K usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 62.89 0.18 % $ 128 B usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 58.59 4.29 % $ 7.04 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 159.75 5.35 % $ 20.9 B usaUSA
Amgen Amgen
AMGN
$ 467.97 0.59 % $ 252 B usaUSA
Orgenesis Orgenesis
ORGS
- -33.86 % $ 61.2 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc
JAZZ
$ 248.31 1.17 % $ 15.1 B irlandaIrlanda
Johnson & Johnson Johnson & Johnson
JNJ
$ 280.31 -0.17 % $ 675 B usaUSA
Kala Pharmaceuticals Kala Pharmaceuticals
KALA
$ 0.17 0.64 % $ 1.39 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 1.49 -1.97 % $ 3.67 B israelIsrael
Sage Therapeutics Sage Therapeutics
SAGE
- - $ 527 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.59 -2.76 % $ 2.62 M israelIsrael
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
$ 1.13 8.17 % $ 260 M usaUSA
Paratek Pharmaceuticals Paratek Pharmaceuticals
PRTK
- - $ 121 M usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
- - $ 58.1 M usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 2.9 -3.5 % $ 240 M usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
$ 1 437.4 0.36 % $ 1.29 T usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.09 -0.24 % $ 195 M israelIsrael
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
GeoVax Labs GeoVax Labs
GOVX
$ 2.13 -20.4 % $ 2.04 M usaUSA
Unity Biotechnology Unity Biotechnology
UBX
- -33.41 % $ 3.37 M usaUSA